Physician profile
Reeti Chawla
NPI 1215193479
$2,183.67
in general payments reported to CMS, 2019-2025
26 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $166 · 2021: $289 · 2022: $452 · 2023: $371 · 2024: $281 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $968.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $308.37 | 2019-2025 | |
| Medtronic, INC. | $172.71 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Abbott Laboratories | $156.76 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $154.88 | 2021-2025 | Lupron Depot |
| Ascendis Pharma Endocrinology INC | $154.24 | 2022-2024 | |
| Rhythm Pharmaceuticals, INC. | $131.09 | 2021-2025 | Imcivree, Imcivree |
| Novo Nordisk INC | $129.96 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $100.36 | 2019-2021 | |
| Beta Bionics, INC. | $95.96 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $87.93 | 2019-2023 | Baqsimi |
| Xeris Pharmaceuticals, INC. | $76.87 | 2021-2024 | Gvoke Hypopen |
| Tolmar, INC. | $73.69 | 2023-2025 | Fensolvi |
| Tolmar Pharmaceuticals, INC. | $71.63 | 2022 | |
| Insulet Corporation | $65.57 | 2019-2024 | Omnipod |
| Intuity Medical INC | $58.12 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $55.50 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $49.55 | 2021 | |
| Ferring Pharmaceuticals INC. | $44.33 | 2019 | |
| Soleno Therapeutics, INC. | $31.28 | 2025 | Vykat Xr |
| Companion Medical, INC. | $29.25 | 2020 | |
| Neurocrine Biosciences, INC. | $28.92 | 2025 | |
| Eton Pharmaceuticals, INC. | $23.78 | 2025 | Khindivi, Alkindi, Increlex |
| Sanofi-Aventis U.S. LLC | $22.85 | 2023 | |
| Ascensia Diabetes Care US INC. | $20.68 | 2024 | |
| Dexcom, INC. | $19.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reeti Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.